We serve Chemical Name:2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid CAS:868151-10-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid
CAS.NO:868151-10-4
Synonyms:pl2615-1
Molecular Formula:C18H26N2O5
Molecular Weight:350.40900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.31000
Exact Mass:350.18400
LogP:2.24940
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like pl2615-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pl2615-1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,pl2615-1 Use and application,pl2615-1 technical grade,usp/ep/jp grade.
Related News: No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid manufacturer AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid supplier AstraZeneca Plc said on Monday that its cancer drug met the main goal of delaying the progression of a form of lung cancer. 2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid vendor No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 2-(3-methoxyphenyl)-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]acetic acid factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.